Tag Directory / HEALTHCARE     showing 121–140 of 610   RSS



How state laws can stymie research into your ancestors' psychiatric records

abcnews - Frustrated family members and others have been pushing for law changes in New York and other states that would allow the release of mental health records of long-dead ancestors

AI Summary: Legal researchers warn that a patchwork of state statutes and privacy rules is blocking access to historical psychiatric records needed for family‑history and population‑level studies. The restrictions complicate efforts to understand intergenerational mental‑health patterns and hamper reproducible research, leaving scientists to navigate inconsistent consent, archival access, and litigation risks.

6 wks / abcnews




Stem cells have potent potential for diabetes treatment

medicalxpress - Humans have around 30 trillion cells in our adult bodies. Amazingly, each of these cells came from a handful of about 100 stem cells in the earliest days of development. The ability of these embryonic stem cells to turn into any cell type makes them pluri…

AI Summary: Researchers report stem cell–based approaches can replenish insulin‑producing cells and restore glycemic control in diabetes models, offering a potential path beyond daily insulin injections. Early findings suggest significant therapeutic promise, but scientists stress that safety, durability, and immune‑rejection hurdles must be cleared before these techniques graduate from experimental hope to standard care.

6 wks / livescience




An Ebola treatment tent is set ablaze again in eastern Congo with 18 suspected cases escaping

abcnews - A tent used for Ebola treatment in eastern Congo has been set on fire for the second time this week

AI Summary: In eastern Congo, an Ebola treatment tent was set ablaze, allowing at least 18 suspected patients to escape and disrupting outbreak containment efforts. The incident has drawn international scrutiny, with Congolese health officials publicly criticizing restrictive U.S. travel measures that complicate cross-border response and community trust.

5 wks / abcnews

5 wks / abcnews

5 wks / abcnews

5 wks / abcnews

5 wks / abcnews

5 wks / bbc

5 wks / abcnews

5 wks / abcnews

6 wks / abcnews

6 wks / abcnews

6 wks / abcnews

6 wks / abcnews

6 wks / abcnews

6 wks / abcnews

6 wks / abcnews

6 wks / abcnews

6 wks / abcnews

6 wks / abcnews

6 wks / abcnews

7 wks / abcnews




Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop

Ayisha Sharma / endpoints - Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients. The small-molecule drug, known as BIIB122, missed the study’s ...

AI Summary: After disappointing mid‑stage results, developers have stopped advancement of a candidate Parkinson’s therapy for non‑genetic forms of the disease. The setback underscores the challenges of translating promising mechanisms into clinical benefit and will force sponsors to reassess pipelines and patient selection strategies.




Abridge names chief technology officer

Giles Bruce / beckershospitalreview - San Oo has been named chief technology officer of healthcare AI startup Abridge. Mr. Oo was most recently senior vice president of engineering at AI workspace developer Notion. He previously cofounded two tech companies that were acquired by LinkedIn and …

AI Summary: Abridge has appointed a new chief technology officer to lead its product and engineering strategy, signaling a push to scale its clinical AI tools and platform capabilities. The hire aims to strengthen technical leadership, accelerate development timelines, and reassure customers that the company intends to keep up with the fast-paced demands of healthcare AI — which, ironically, keeps hiring to stop churn.


AI startups scale via health system partnerships


Practical challenges: accessibility, training, oversight of clinical AI

6 wks / oncodaily

6 wks / oncodaily


All Other Stories

6 wks / oncodaily




CommonSpirit $3.4B in the red amid billing contract exit, operational woes

Rebecca Pifer Parduhn / healthcaredive - The Catholic nonprofit giant’s expenses well outstripped revenue in the most recent financial quarter. Though the outcome was mostly due to one-time items, CommonSpirit also continues to struggle with boosting core operations.

AI Summary: CommonSpirit reported a multi‑billion‑dollar shortfall tied to operational challenges and the exit from a major billing contract, recording a substantial loss and a weakened operating margin in the quarter. The results have spurred leadership to reassess financial strategy and cost controls as the system navigates recovery and operational stabilization.




FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

Lei Lei Wu / endpoints - The FDA has approved the TROP2-directed antibody-drug conjugate Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead. The approval marks Datroway’s third, after ...

AI Summary: Daiichi Sankyo and AstraZeneca’s breast cancer therapy Datroway has cleared key regulatory hurdles, winning FDA approval and earning backing from European regulators. The approvals validate pivotal trial results and pave the way for clinical adoption in the indicated patient population, prompting clinicians to prepare for integration into treatment pathways and health systems to weigh formulary and access decisions.


Clinicians weigh Datroway’s role in TNBC care

6 wks / oncodaily

6 wks / oncodaily

7 wks / oncodaily


FDA win and market stakes for Datroway

6 wks / oncodaily


All Other Stories

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

7 wks / bbc




Nearly 10% of surgeons are leaving the profession within 8 years

medicalxpress - Surgeons are an integral part of the health care system, supplying critical and urgent care in nearly every field of medicine. But surgeons are already in short supply, with the gap between the number needed and the number working expected to get worse.

AI Summary: A recent report reveals that roughly one in ten surgeons leave clinical practice within eight years of starting, spotlighting a troubling attrition rate that threatens surgical capacity. The findings point to burnout, workload and systemic pressures as likely drivers and underscore the need for retention strategies, training support and policy changes to stabilize the surgical workforce.

5 wks / oncodaily




Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer

Kathleen Medora / aacr - CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic canc…

AI Summary: Researchers propose lowering the CA19‑9 threshold to identify additional patients at high risk for pancreatic cancer. The analysis indicates the new cutoff improves detection of potentially dangerous cases without an unmanageable rise in false positives, offering a straightforward diagnostic tweak that could prompt earlier workups and treatment decisions.

6 wks / oncodaily

6 wks / newscientist

6 wks / oncodaily




Providence shuts down most insurance businesses for 2027

Rebecca Pifer Parduhn / healthcaredive - The nonprofit giant has offered health insurance for decades. But recent challenges, including higher costs and regulatory changes, have placed Providence in an untenable position, according to the integrated system’s CEO.

AI Summary: Providence announced plans to shut down or substantially scale back its insurance businesses by 2027, citing unsustainable operations and strategic misalignment. The health system will refocus on core care delivery, a move that will ripple through regional insurance markets, affect covered members, and require careful transition planning to maintain access.




BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test

Reynald Castaneda / endpoints - BioMarin’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results in a late-stage study. Patients with the condition don't produce enough of the ENPP1 enzyme, which generates plasma inorganic pyrophosphate .…

AI Summary: BioMarin reported a Phase 3 trial that failed to show clinical benefit for a rare‑disease therapy, undermining prior optimism and clouding the drug’s development pathway. The mixed late‑stage results force a strategic reassessment, cooling investor expectations and leaving researchers and patients waiting for next steps or alternative approaches.




Skin cancer cases hit record high in the UK

Sydney Ghazarian / cancerresearchuk - New analysis shows that melanoma skin cancer rates in the UK have reached a new high of 20,000 cases per yearThe post Skin cancer cases hit record high in the UK appeared first on Cancer Research UK - Cancer News.

AI Summary: The UK has recorded its highest-ever number of skin cancer cases, with an alarming rise in the most dangerous presentations. Public health experts point to changing sun behaviours and inadequate sun protection as likely contributors. The surge signals strain on dermatology services and a need for clearer messaging—because sunscreen confusion apparently remains a public health hobby.

6 wks / bbc

6 wks / oncodaily

7 wks / bbc




Quorum Health strikes deal to become nonprofit

Kelly Gooch / beckershospitalreview - Quorum Health, a for-profit system headquartered in Brentwood, Tenn., has signed a definitive agreement with nonprofit health system Healthside Partners to transition Quorum into a nonprofit organization spanning 11 hospitals across nine states. With the …

AI Summary: Quorum Health agreed to become a nonprofit through a transaction with Healthside Partners to avert insolvency, rescue struggling hospitals, and stabilize finances. Executives frame the conversion as a survival strategy to maintain care access, restructure operations, and shift priorities from profitability to community health amid mounting fiscal pressure.




Blog Post
Quorum Health has agreed to convert from a for-profit to a nonprofit system through a definitive transaction with nonprofit Healthside Partners, officials said. The deal would move Quorum’s 11 hospitals in nine states into nonprofit status and is intended to shore up finances and preserve care in rural communities (Becker’s; Healthcare Dive). Quorum, based in Brentwood, Tenn., has pursued years of restructuring — including bankruptcy-related restructuring and portfolio reductions after spinning off from Community Health Systems about a decade ago — and CEO Chris Harrison framed the nonprofit move as one of survival amid mounting operational and financial pressures (Becker’s). Under the agreement, Quorum plans to expand charity care programs and to invest more than $300 million in capital projects through 2029. Executives say the conversion will help the system access new sources of financial support and shift priorities away from profitability toward community health and stability for struggling hospitals (Becker’s; FierceHealthcare). The transaction is expected to close in the fall. The move comes against a broader backdrop of rising hospital bad debt and charity-care pressures nationally, which industry data show have increased year over year (Becker’s).

GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor

Reynald Castaneda / endpoints - European healthcare investor GHO Capital and asset management firm CBC Group are set to join forces, with the new entity to manage over $21 billion. In a Wednesday release, they said ...

AI Summary: GHO Capital and CBC Group have agreed to combine their healthcare investment platforms to create roughly a $21 billion specialist investor focused on health assets. The tie-up consolidates capital and deal teams to chase larger transactions across care delivery, pharma and tech—because apparently healthcare needed a bigger private-equity behemoth.

6 wks / oncodaily




Toronto Rock take NLL Cup with win over Halifax Thunderbirds

Denio Lourenco / citynews - Owen Hiltz and Chris Boushy each had three goals and an assist, Mark Matthews had a goal and three assists, and Nick Rose made 34 saves as the Toronto Rock defeated the Halifax Thunderbirds 12-7 to win the National Lacrosse League championship on Sunday a…

AI Summary: A clinical study shows that delivering just two ablative radiotherapy sessions over eight days achieves effective control of localized prostate cancer without adding side effects, offering a dramatically shorter, patient‑friendly regimen. If adopted more widely, the approach could reduce treatment burden, clinic visits and health‑system costs while maintaining cancer control.

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

7 wks / oncodaily




Nourish Secures $100M for Metabolic Health Clinic

Marissa Plescia / medcitynews - Nourish’s Series C round was led by Menlo Ventures, with participation from Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak and Operator Partners.The post Nourish Secures $10…

AI Summary: Nourish secured a $100 million funding round to expand its virtual metabolic-health and nutrition care model, doubling down on physician integration and broader clinical rollout. The company plans to scale tele-nutrition services and deepen provider partnerships to treat metabolic disease at home, aiming to convert weight and metabolic management into reimbursable medical care.




Anxiety-related pediatric visits in primary care rise 300%: Study

Ella Ruder / beckershospitalreview - Anxiety-related visits in pediatric primary care settings increased 300% between 2014 and 2023, according to a May 18 study published in JAMA Network Open. Researchers from Boston University’s School of Public Health and the Harvard Pilgrim Health Care In…

AI Summary: Analysis reveals a roughly 300% increase in anxiety-related visits to primary care among children, straining clinics and signaling a nationwide mental-health wave. Primary-care physicians are now de facto child mental-health providers, with experts urging expanded behavioral services, school-based supports and parental resources to manage what’s become an urgent, system-wide demand.




FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure

Frank Vinluan / medcitynews - AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and for AstraZeneca, which has been looking for new drugs with blockbuster pote…

AI Summary: The FDA has approved a first-in-class oral agent that uses a novel mechanism to lower resistant hypertension, offering an alternative for patients who haven’t responded to standard therapies. The move expands treatment options and signals renewed industry focus on innovative vascular targets — finally something for stubborn blood pressure to complain about.




CMS finalizes major changes to ACA exchanges, including greater access to catastrophic plans

Rebecca Pifer Parduhn / healthcaredive - The Trump administration continues to open the doors to the cheap, high-deductible coverage, to the worry of insurance experts and stakeholders in the healthcare industry.

AI Summary: In a sweeping final rule, CMS loosened constraints on ACA marketplace offerings to broaden consumer choice — including expanded access to catastrophic plans and relaxed limits on non-standard plan designs. The changes aim to reshape the 2027 exchanges, boost affordability and enrollment flexibility, and hand insurers new product wiggle room while regulators expect close scrutiny.


CMS final rule loosens plan design, expands catastrophic access


Insurers exit and consumers pivot to cheaper alternatives


Rising costs and shrinking ACA enrollment threaten markets




Kicking Off the Cancer Planners Forum in Geneva – UICC

oncodaily - Union for International Cancer Control (UICC) shared a post on LinkedIn: “We’re excited to kick off the Cancer Planners Forum in Geneva today! Convening national leaders responsible for cancer control planning, […]

AI Summary: The UICC Cancer Planners Forum in Geneva brought policymakers, clinicians, and public‑health leaders together to map national cancer control strategies, prioritize cervical cancer elimination, and foster implementation partnerships. The forum emphasized practical planning, stakeholder engagement, and resource‑sensitive solutions to turn plans into measurable improvements in prevention, screening, and care delivery.


Cervical cancer elimination and clinical partnerships

7 wks / esmo

7 wks / oncodaily

7 wks / oncodaily


Forum launch and wrap-up in Geneva

7 wks / oncodaily

1 month / oncodaily

1 month / oncodaily


National cancer planning and policy priorities

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily


All Other Stories

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / esmo

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / esmo

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

7 wks / esmo




Blog Post
The Union for International Cancer Control (UICC) convened the Cancer Planners Forum in Geneva, bringing together national cancer-control leaders, policymakers, clinicians and public‑health experts to advance practical planning and implementation. UICC reported 120 participants from 54 countries, including 45 cancer planners from 42 countries. Over the course of the forum — described by participants including UICC President‑Elect Zainab Shinkafi‑Bagudu, McCabe Centre’s Hayley Jones, and Pfizer’s Jennifer Young — delegates worked to map national cancer control strategies, prioritize cervical cancer elimination, and build implementation partnerships. The meeting emphasized stakeholder engagement and resource‑sensitive, operational approaches to turn plans into measurable improvements in prevention, screening and care delivery. UICC announced the forum both at its kickoff and on conclusion as a successful convening of planners and partners.

Back to Top


HEALTHCARE Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Novo Nordisk, Pancreatic Cancer, Alzheimer's disease, Neuroscience and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.